Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback